Oppenheimer Holdings Inc. reports developments tied to its wealth management, securities brokerage, investment banking, and capital markets businesses conducted through Oppenheimer & Co. Inc. and related entities. Recurring updates include quarterly earnings, advisory and underwriting activity, sales and trading conditions, private client division changes, and asset management-related measures within the Wealth Management segment.
Company news also covers additions to investment banking and public finance capabilities, including equity capital markets, debt private placements, municipal underwriting and trading, and sector-focused advisory coverage. Governance, capital actions, and legal or compensation items that affect reported results may also appear in company disclosures.
Oppenheimer (NYSE:OPY) named Chris DeFalco and John Hyland as Co-Heads of its Equity Capital Markets (ECM) investment banking group, effective March 24, 2026. Both will serve on the firm's Investment Banking Commitment Committee while Peter Bennett shifts to lead Corporate Executive Services to connect Investment Banking and Wealth Management.
DeFalco has completed more than 285 equity and equity-linked offerings and led the firm's SPAC practice; Hyland has led over 200 equity offerings and joined Oppenheimer in 2021.
Oppenheimer (NYSE: OPY) named Eric Nortman Managing Director and Head of Debt Private Placements on March 17, 2026, launching a dedicated Debt Private Placements Group to expand private credit financing solutions for investment banking clients.
Nortman will be based in New York, report to Co-Heads of Investment Banking Rob Lowenthal and Gilbert Dychiao, and work with Fixed Income to execute private debt transactions.
Oppenheimer (NYSE: OPY) appointed Vien Le as Managing Director in its Public Finance Investment Banking Group, effective Feb. 25, 2026. Le will be based in Los Angeles and report to Beth Coolidge, Head of Public Finance.
Le brings 20+ years of municipal finance experience, will focus on California and support clients across the West, and previously served at Stern Brothers, UBS and other firms.
Oppenheimer Holdings (NYSE: OPY) reported record results for Q4 and full-year 2025. Q4 net income $74.4M ($7.08 basic EPS) vs $10.7M last year; Q4 revenue $472.6M (+25.9%). For FY-2025, net income $148.4M ($14.13 basic EPS) and revenue $1.64B (+14.4%).
Strength came from Wealth Management AUM record of $55.2B and a Capital Markets revenue surge driven by investment banking activity. The firm declared a $1.00 special dividend and repurchased shares during 2025.
Oppenheimer Holdings (NYSE: OPY) declared a special cash dividend of $1.00 per share on Class A non-voting and Class B voting common stock, payable January 9, 2026 to shareholders of record at the close of business on December 26, 2025.
The aggregate payment is expected to be approximately $10.5 million, and the company said the special dividend will be funded through its existing cash management activities. Management framed the dividend as recognition of improved operating results and financial position.
Oppenheimer (NYSE: OPY) announced on Dec. 8, 2025 that Kostas Biliouris, Ph.D., joined as Managing Director on its Biotech Research Team, based in New York and reporting to William Bird.
Biliouris previously worked at BMO Capital Markets covering genetic medicines, was a VP in biotech research at Morgan Stanley, and held drug development and product strategy roles at Novartis. His background includes a Ph.D. in biochemical engineering and scientific publications with Biogen, Ionis, Merck, Novartis, and the FDA. The firm said the hire strengthens Oppenheimer's long-standing healthcare and biotech research franchise and expands coverage across genetic medicines and related sectors.
Oppenheimer (NYSE: OPY) announced that Keith Peterson has been appointed Managing Director and Head of Cash Equity Sales and Trading, effective Nov. 17, 2025.
Peterson will report to John Hellier, oversee supervisory and operational activities for the equity sales and trading team, and serve as co-chair of the Firm's new Capital Markets Business Development Committee to drive cross-asset collaboration between investment banking, research, sales and trading. He joins with more than two decades of equity markets experience, most recently as Partner and Head of Sector Trading at William Blair and prior trading roles at Credit Suisse. Leadership said the hire supports Oppenheimer's efforts to expand its equities platform and deepen client service.
Oppenheimer Holdings (NYSE: OPY) reported 3Q-2025 revenue of $424.4M, up 13.7% year-over-year, and net income of $21.7M or $2.06 basic EPS, down versus 3Q-2024. Management cited stronger equity underwriting, higher commissions and record AUM as drivers.
Key operational highlights: Capital Markets revenue $162.1M (+30.7%), Wealth Management revenue $259.7M (+5.6%), and AUM reached a record $55.1B at September 30, 2025. Compensation expense rose materially, including $13.5M pre-tax for liability-based awards tied to the share price, pressuring margins and EPS.
Oppenheimer (NYSE: OPY) hired Guy T. Logan as Managing Director, Head of Infrastructure & Mid-Atlantic Region in its Public Finance Investment Banking Division, reporting to Beth Coolidge.
Logan brings more than 30 years of municipal finance experience, served as senior or lead banker on >250 transactions totaling $55 billion, and recently led Jefferson County, Alabama's $2.2 billion 2024 refinancing. His prior roles include Raymond James and 26 years at Citigroup Global Markets.
The move is presented as part of Oppenheimer's continued expansion of its Public Finance platform and senior bench.
Oppenheimer (NYSE: OPY) announced on October 6, 2025 that James Yoo was named Managing Director in its Healthcare Equity Capital Markets Investment Banking Group.
The company states Mr. Yoo brings 27 years of industry experience and will focus on biotechnology equity capital markets, including PIPEs, follow-on offerings, CMPOs and registered direct transactions. According to the PR, Yoo previously served as Oppenheimer's Healthcare Specialist on the Sales & Trading desk since 2023 and held roles at Piper Sandler, Mizuho, and Nomura. Management comments in the release highlight Yoo's execution track record and biotech relationships as strengthening Oppenheimer's Healthcare ECM platform.